Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550
monotherapy (5 mg, 15 mg, and 30 mg twice daily [BID]) versus placebo administered over 6
weeks for the treatment of the signs and symptoms of subjects with active rheumatoid
arthritis (RA).